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Integrin-Targeted, Short Interfering RNA Nanocomplexes 
for Neuroblastoma Tumor-Specific Delivery Achieve MYCN 
Silencing with Improved Survival
Aristides D. Tagalakis, Vignesh Jayarajan, Ruhina Maeshima, Kin H. Ho, Farhatullah Syed, 
Lin-Ping Wu, Ahmad M. Aldossary, Mustafa M. Munye, Talisa Mistry, Olumide Kayode Ogunbiyi, 
Arturo Sala, Joseph F. Standing, Seyed M. Moghimi, Andrew W. Stoker, and Stephen L. Hart*
The authors aim to develop siRNA therapeutics for cancer that can be adminis-
tered systemically to target tumors and retard their growth. The efficacy of sys-
temic delivery of siRNA to tumors with nanoparticles based on lipids or polymers 
is often compromised by their rapid clearance from the circulation by the liver. 
Here, multifunctional cationic and anionic siRNA nanoparticle formulations are 
described, termed receptor-targeted nanocomplexes (RTNs), that comprise pep-
tides for siRNA packaging into nanoparticles and receptor-mediated cell uptake, 
together with lipids that confer nanoparticles with stealth properties to enhance 
stability in the circulation, and fusogenic properties to enhance endosomal 
release within the cell. Intravenous administration of RTNs in mice leads to pre-
dominant accumulation in xenograft tumors, with very little detected in the liver, 
lung, or spleen. Although non-targeted RTNs also enter the tumor, cell uptake 
appears to be RGD peptide-dependent indicating integrin-mediated uptake. 
RTNs with siRNA against MYCN (a member of the Myc family of transcription 
factors) in mice with MYCN-amplified neuroblastoma tumors show significant 
retardation of xenograft tumor growth and enhanced survival. This study shows 
that RTN formulations can achieve specific tumor-targeting, with minimal clear-
ance by the liver and so enable delivery of tumor-targeted siRNA therapeutics.
DOI: 10.1002/adfm.202104843
1. Introduction
Neuroblastoma is the most common solid 
tumor of childhood, accounting for 8–10% 
of all childhood cancers and 15% of cancer-
related deaths in children.[1] The current 
treatment for neuroblastoma patients with 
severe disease is chemotherapy, followed 
by surgical resection or radiotherapy.[2] 
Those diagnosed over 1 year of age have 
a less favorable outlook and often fail to 
respond even to these aggressive combi-
nations of therapy while others frequently 
relapse, and so alternative treatments are 
needed.
Gene amplification of MYCN in neu-
roblastoma is associated with a particu-
larly poor prognosis and occurs in about 
20% of cases.[3] MYCN encodes N-Myc, a 
member of the Myc family of transcription 
factors, controlling expression of genes 
involved in proliferation, cell growth, pro-
tein synthesis, metabolism, apoptosis, 
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and differentiation.[4] N-Myc also interacts with apoptotic fac-
tors such as BCL2[5] or p53 and may inhibit apoptosis while, 
conversely, over-expression of N-Myc may also drive apop-
tosis.[6] MYCN amplification leads to over-expression of N-myc, 
although, interestingly, there are cases where protein levels are 
increased in tumors without genome amplification.[7] MYCN 
expression occurs normally at fetal stages of neurogenic tissue 
development with little or none expressed in adult tissues and 
so neuroblastoma-associated MYCN expression is highly tumor 
specific.[8] We and others have demonstrated therapeutic effects 
of short interfering RNA (siRNA)-mediated MYCN silencing, 
including cell differentiation or apoptosis, in neuroblastoma 
models in vitro and in vivo with as little as 50% reduction of 
MYCN mRNA.[4a,9] MYCN is, thus, an attractive therapeutic 
target for neuroblastoma associated with MYCN amplification 
or N-myc over-expression, as it offers a safe, tumor-specific 
target in MYCN-amplified tumors.[9a,10]
We propose that a tumor-specific, MYCN-targeted siRNA 
(siMYCN) treatment for disseminated neuroblastoma may be 
achieved by systemic administration of the siRNA encapsu-
lated in a suitable nanoparticle formulation. Neuroblastoma 
tumors are highly vascularized with a leaky endothelium that 
may enable extravasation of nanoparticles into the tumor from 
the circulation,[11] or by endothelial transcytosis.[12] We have 
previously described a nanocomplex formulation that enabled 
tumor-specific plasmid DNA (pDNA) transfection, with very 
little transfection of liver or other organs[13] and demonstrated 
pDNA-expressed cytokine adjuvant immunotherapy;[13b] but 
siRNA therapeutics offer alternative targets and strategies in 
cancer therapies, such as ectopically expressed oncogenes.
Receptor-targeted nanocomplexes (RTNs) comprise a formu-
lation of integrin-targeting peptides and lipids which, on mixing 
with nucleic acids at optimized ratios form self-assembling 
complexes.[13b,14] The peptide contains a cationic, sixteen-lysine 
domain for nucleic acid packaging, and a short cyclic peptide 
ligand, GACRGDCLG, which binds to integrin cell surface recep-
tors.[15] Integrins are highly expressed on tumor cells and exhibit 
non-polarized membrane distribution instead of the basolateral 
distribution seen in healthy tissues, which increases integrin 
accessibility to targeting ligands, such as RGD peptides.[13b,16] The 
RTN lipid components may be cationically or anionically charged, 
affecting the surface charge of the resulting nanocomplexes[14f ] 
while PEGylated liposomes are widely used to shield charge, and 
confer stealth properties.[14e] The neutral, fusogenic dioleoylphos-
phoethanolamine is essential to mediate endosomal release of 
the nucleic acids.[17] Thus, RTNs contain multiple functionalities 
to overcome cellular and extracellular barriers to tumor-targeted 
transfection and have achieved pDNA transfection of tumors of 
more than 90% in a murine syngeneic model of neuroblastoma.[13]
Our aim in this study was to develop novel RTNs for 
siMYCN delivery to neuroblastoma tumors and to evaluate 
their in vivo biodistribution, therapeutic effects, and toxicity. 
We have evaluated and compared the targeted delivery and ther-
apeutic potential of cationic and anionic-PEGylated formula-
tions and anionics offer the prospects of reduced toxicity in vivo 
and greater cell-targeting specificity.[14f ] RTNs were assessed 
for systemic delivery of siMYCN formulations to neuroblas-
toma tumor xenografts and we describe a pharmacokinetic/
pharmacodynamic model of the effects of treatment on tumor 
growth.
2. Results and Discussion
2.1. Biophysical Characterization of Nanocomplexes
The size, charge and stability of siRNA lipid/peptide RTNs were 
first determined to assess their suitability for in vivo use. The 
sizes of cationic, cationic-PEG, and anionic-PEG siRNA nano-
complexes were 110.7 ±  17.7, 149.4 ± 28.4, and 140.6 ±  11.4 nm, 
respectively, with corresponding zeta potentials of +43.1  ±  7.4, 
+44.1  ±  11.2, and −43.7  ±  11.1  mV (Figure 1A). The polydis-
persity index (PDI) measurements of cationic, cationic-PEG, 
and anionic-PEG siRNA nanocomplexes were 0.402  ±  0.028, 
0.344  ±  0.157, and 0.188  ±  0.027, respectively. Each nanocom-
plex formulation was stable in water while non-PEGylated cati-
onic nanocomplexes aggregated rapidly in PBS to ≈1290  nm 
(Figure 1B). The short PEG lipids (PEG2000) and their low den-
sity in the RTN formulation were selected to confer particle 
stability in physiological solutions without excessively com-
promising their transfection efficiency. PEGylated cationic and 
anionic nanocomplexes were stable in PBS at ≈205  nm and 
≈147  nm, respectively (Figure  1B), demonstrating the antici-
pated shielding effect of this PEGylation strategy.[13a,18]
An alternative sizing modality, nanoparticle tracking analysis 
(NTA) (Table S1, Supporting Information), showed cationic-
PEGylated formulations with a size of 144 nm, very similar to 
the zetasizer estimation of 149 nm, although the anionic-PEG 
RTNs were somewhat larger by NTA at 243  nm compared to 
140 nm by zetasizer analysis. These discrepancies presumably 
arise from sample polydispersity, since the average hydrody-
namic diameters obtained by DLS is a measure of total scat-
tered light from an ensemble of particles, whereas in NTA the 
measurements are based on the Brownian motion through 
video analysis and tracking the movement of individual par-
ticles. Negative-staining, transmission electron microscopy 
(TEM) indicated that anionic-PEG and cationic-PEG nanocom-
plexes were both mainly spherical with sizes consistent with 
light scattering data (Figure 1E,F).
In a serum-stability assay, performed as described previ-
ously,[19] the turbidity of the cationic-PEG nanocomplexes in 
mouse serum (50%) was approximately half that of the cationic-
non PEG counterpart, whereas the anionic-PEG nanocomplexes 
showed the least aggregation (Figure 1C), due to the steric bar-
rier of PEG in minimizing interaction with serum proteins.[14e] 
On the basis of these observations, PEGylated cationic and ani-
onic formulations were selected for in vivo use.[19]
The siRNA packaging efficiency of PEGylated nanocom-
plexes and their dissociation potential in response to heparin 
was then assessed. While extracellular stability is an essential 
requirement for an effective siRNA delivery formulation, 
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transfection efficiency is also dependent on release of siRNA 
within the cell following internalization.[20] Nanocomplex dis-
sociation in the presence of heparin reflects their potential to 
release siRNA in the cytoplasm where high concentrations of 
anions such as nucleic acids, and sialic acid residues, will be 
encountered.[14e,21] PicoGreen-labeled siRNA was formulated 
into nanocomplexes to assess packaging efficiency. Cationic 
PEGylated and non-PEGylated formulations displayed similar 
levels of PicoGreen fluorescence quenching in the absence of 
heparin, while that of anionic formulations was slightly less 
quenched, although greater than 90%, indicating that all for-
mulations encapsulated the siRNA effectively (Figure  1D). 
PEGylation appeared to reduce the stability of the cationic 
nanocomplexes to heparin, while anionic formulations were 
the least stable, indicating the possibility of easier release of 
siRNA from the nanocomplex.
Figure 1. Biophysical characteristics of cationic non-PEG, cationic-PEG, and anionic-PEG nanocomplexes. A) Nanoparticle size and surface charge was 
measured by dynamic light scattering. B) Size measurements of nanocomplexes over a 1-h period with nanocomplexes made in either water or PBS. 
C) The effect of 50% mouse serum concentration on the relative turbidity of cationic, cationic-PEG, and anionic-PEG nanocomplexes over a 60 min 
incubation period. A cationic liposome (DOTMA/DOPE) was used as a positive control of the assay. D) The dissociation properties of cationic and 
anionic-PEGylated nanocomplexes were investigated from PicoGreen fluorescence of nanocomplexes, after incubation with heparin (0–1  U  mL−1), 
expressed as a percentage of relative fluorescence units (RFU) relative to free siRNA. Negative staining TEM was used to visualize, E) anionic PEG and 
F) cationic-PEG nanocomplexes. Scale bar = 100 nm. DL= double-layered.
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2.2. In Vitro Transfection Efficiencies
Receptor-mediated uptake of nanoparticles enhances uptake 
into targeted cells while minimizing non-specific delivery.[22] 
Integrins are heterodimeric receptors normally involved in cell–
cell and cell–extracellular matrix interactions. In tumor cells, 
the normal polarized, basolateral display of integrins breaks 
down, making them more accessible to targeting ligands thus 
offering tumor-specific targets.[16b] In this study, we used pep-
tide ME27 (K16RVRRGACRGDCLG), containing the conserved 
integrin-targeting motif Arg-Gly-Asp (RGD) motif in a cyclic 
form, which targets αvβ3, αvβ5, and α5β1 integrins. This motif 
is followed by a K16 domain for electrostatic siRNA packaging, 
and an RVRR domain, which is cleavable by the endosomal 
enzymes cathepsin B and furin. We have shown previously that 
cleavable peptide linkers enhance intracellular nanocomplex 
disassembly, and so enhance transfection efficiency.[13a,23]
An optimized siRNA, siMYCN-3, was selected from prelimi-
nary MYCN silencing transfections (Figure S1A,B, Supporting 
Information) then silencing efficiency of MYCN in Kelly and 
LAN-5 cells was assessed by qRT-PCR and compared with 
different RTN formulations. Cationic non-PEGylated formu-
lations achieved the highest levels of silencing at >60%  and 
>80% in both cell lines (Figures 2A and 2B, respectively). We 
have shown elsewhere that silencing of MYCN at this level 
reduces protein on western blots and induces apoptosis in 
Kelly cells and differentiation in another neuroblastoma cell 
line, IMR32.[9b]] While PEGylation slightly reduced silencing 
efficiency in vitro, we focused primarily on PEGylated formu-
lations for in vivo delivery due to their stability and superior 
resistance to aggregation compared with non-PEGylated for-
mulations. Cell viability following transfections with control 
siRNA showed that the cationic-PEG nanocomplexes resulted 
in slightly increased cytotoxicity in both Kelly and LAN-5 cells 
(Figure  2C), although viability remained at about 90% in 
both cell lines, while the anionic-PEGylated nanocomplexes 
did not induce any apparent cytotoxicity. These results are 
consistent with previous reports of the cytotoxicity of cationic 
liposomes.[24]
2.3. Complement Activation Assay, Cell Viability,  
and Cellular Effects
The complement system has an important role in both 
innate and cognate immunity recognizing danger signals 
through pattern recognition and clearance by neutrophils, 
monocytes, and tissue macrophages.[25] However, uncon-
trolled complement activation may elicit acute adverse reac-
tions and promote tumor growth.[26] To assess complement 
activation with RTN formulations, we incubated human 
serum with cationic-PEG and anionic-PEG formulations 
at comparable surface areas (23 and 46  cm2), as comple-
ment activation is surface area-dependent. Surface areas 
were determined from average size measurements of each 
sample by the NTA (Table  S1 and Figure  S2, Supporting 
Information). The particle concentration values imply a 
siRNA molecular content per particle of ≈3000 for anionic-
PEG and ≈5000 for cationic PEG nanoparticles. Meas-
urement of the complement-activation products, sC5b-9 
and C5a showed a slight increase in serum C5a levels for 
the cationic-PEG formulation (p  <  0.05) and anionic-PEG 
formulation (p  <  0.01) compared with water and PBS con-
trols (Figure 3A), while sC5b-9 remained at background 
levels (Figure  3B). Zymosan was used as a positive con-
trol for complement activation and induced high levels of 
C5a and sC5b-9 products (201.3  ±  10.1  ng  mL−1  C5a, and 
31 678 ± 1 583 ng mL−1 sC5b-9, respectively). Thus, cationic-
PEG and anionic-PEG RTN formulations displayed negli-
gible levels of complement activation, which contrasts with 
the PEGylated liposome product, Doxil, which activated 
sC5b-9 at much higher levels (8560 ± 108.1 ng mL−1).[27]
Figure 2. siRNA-mediated silencing of MYCN with nanocomplexes in different cell lines. Cationic non-PEG, cationic-PEG, and anionic-PEG complexes 
were used in transfections with MYCN siRNA in A) Kelly cells and B) LAN-5 cells. Nanocomplexes with non-targeting control siRNA were used in control 
transfections and L2K/siRNA was used as a positive control while untreated cells received no siRNA. qRT-PCR assays were normalized to non-targeting 
control siRNA formulations. C) Viability of Kelly and LAN-5 cells following transfection for 24 h with different nanocomplexes at 100 nm siRNA. Viability 
values were normalized to the untransfected control cells. All transfections were performed in groups of six and mean values were calculated. Asterisks 
indicate comparisons of specific formulations to the control untransfected cells with statistical significance (*p < 0.05; **p < 0.01). DL= double-layered.
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MYCN silencing in neuroblastoma cells is well-known to 
induce apoptosis and indeed here it induced changes in cell mor-
phology consistent with apoptotic cell death including rounding-
up, shrinking, and lower cell density (Figure 4A–G). Cell staining 
with propidium iodide followed by flow cytometry analysis 
for detection of subG1 cells is a convenient way to quantify 
apoptosis.[28] MYCN siRNA transfections increased the subG1 
population to more than 70%, while the PEGylated cationic and 
anionic formulations with irrelevant siRNA induced less than 
10% subG1 cells (Figure 4H). However, irrelevant siRNAs deliv-
ered by cationic RTNs caused more than 30% apoptosis, pointing 
to non-specific, cytotoxicity of the cationic formulation.
Figure 3. Complement activation assays. A) Quantification of complement activation product of A) C5a and, B) SC5b-9, in human serum after incuba-
tion of nanocomplexes with equivalent total surface areas (23 cm2 mL−1 serum and 46 cm2 mL−1 serum, cationic-PEG and anionic PEG nanocomplexes, 
respectively), calculated from the NTA data (Table S1 and Figure S2, Supporting Information). Blank (PBS) and positive control Zymosan (200 µg ml−1), 
were tested during the experiment, as was water. DL = double-layered.
Figure 4. Morphology of MYCN siRNA treated Kelly cells compared to control untransfected cells or irrelevant siRNA treated cells. Cells were trans-
fected with 100 nm siRNAs then imaged 48 h later by phase contrast microscopy. A) Control untreated cells, B) cationic non-PEG non-targeting control 
siRNA, C) cationic non-PEG MYCN siRNA, D) cationic-PEG non-targeting control siRNA, E) cationic-PEG MYCN siRNA, F) anionic-PEG non-targeting 
control siRNA, and G) anionic-PEG MYCN siRNA. H) Quantification of PI-labeled subG1 cells after transfection with MYCN or irrelevant (IRR) control 
siRNAs (n = 2). White arrows indicate dead and dying cells; scale bars are 25 µm. DL = double-layered.
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2.4. In Vivo Biodistribution in Mice with Neuroblastoma 
Xenografts
We next compared the in vivo biodistribution of nanocom-
plexes after intravenous delivery to mice with Kelly cell xeno-
grafts. Cationic-PEG and anionic-PEG, integrin targeted RTNs 
were prepared while cationic non-PEGylated formulations were 
omitted from in vivo studies because of their size instability in 
serum. Live imaging of mice administered with nanocomplexes 
containing siRNA-Dy677-labeled nucleic acids showed that both 
cationic-PEG and anionic-PEG nanocomplexes (Figure 5A) 
accumulated predominantly in tumors at 24  h after adminis-
tration, which was maintained at 48  h (Figure  5B). In further 
experiments, to more closely interrogate the biodistribution 
of the nanocomplexes, mice were administered intravenously 
with nanocomplexes containing fluorescent, FAM-labeled 
siRNA and then organs and tumors were analyzed by fluores-
cent microscopy 24  h later. The anionic-PEG (Figure  5C) and 
the cationic-PEG (Figure  5D) nanocomplexes both showed 
accumulation of fluorescence in tumors with much lower 
levels in other tissues (Figure 5C,D and Figure S3, Supporting 
Information). For example, the fluorescent radiant efficiency 
in tumors from anionic formulations was 4.5-fold higher than 
in the lungs with none detected in other organs (Figure S3A, 
Supporting Information; p <  0.05). Although the cationic-PEG 
formulations showed accumulated fluorescence in lungs, liver, 
and kidneys, respectively, the fluorescent radiant levels were 
9.8-, 56.3-, and 12.5-fold higher in tumors (Figure S3B, Sup-
porting Information). This suggested that, while both cationic 
and anionic formulations accumulated in the tumors, anionic 
nanocomplexes displayed a higher degree of tumor specificity 
compared to their cationic counterparts.
We then assessed whether tumor fluorescence was cell-
associated by staining tumor sections with DAPI to identify 
nuclei (Figure  6). Here, mice were transfected with anionic-
PEG and cationic-PEG formulations containing the integrin 
targeting peptide ME27, or the non-targeting control ME72, in 
which the RGD, integrin-specific motif is substituted for RGE, 
to assess integrin-mediated cell targeting in vivo. Fluorescent 
siRNAs were abundant throughout the tumors transfected with 
all four formulations with no fluorescence observed in tumor 
sections from untreated mice (Figure 6G–I). Fluorescent siRNA 
was clearly located in the cytoplasm of DAPI-stained cells after 
delivery with either anionic-PEG (Figure 6A–C) or cationic-PEG 
Figure 5. Tumor uptake after intravenous administration of cationic-PEG and anionic-PEG formulations. 24 h or 48 h after i.v. administration of nano-
complexes with fluorescently labeled siRNA, mice were either imaged live or culled and tumors and organs were extracted and imaged for fluorescence. 
Mice were imaged live A) 24 h and B) 48 h after intravenous administration of nanocomplexes containing Dy677-labeled siRNA. Organs (heart, lung, 
liver, kidneys, and spleen) and tumor of a mouse that received C) anionic-PEG nanocomplexes and D) cationic-PEG nanocomplexes containing FAM-
labeled siRNA, 24 h after administration.
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(Figure  6D–F) integrin-targeted nanocomplexes. On the other 
hand, while non-targeting, anionic-PEG (Figure  6J–L) and 
non-targeting cationic-PEG nanocomplexes (Figure  6M–O) 
were present in tumors, both appeared to pool in extracellular 
tumor spaces rather than within cells. This suggests that after 
systemic administration, nanocomplex formulations first accu-
mulate within tumors due most likely to the leakiness of the 
tumor neovasculature[29] or endothelial transcytosis.[12] Once 
within the tumor, targeted RTN formulations enter cells by 
integrin-mediated internalization while non-targeted formula-
tions remain extracellular.
2.5. In Vivo MYCN Silencing in Tumor Xenografts
We next investigated the therapeutic potential of siMYCN deliv-
ered by our nanocomplexes to mice with Kelly cell xenografts. 
Tumors showed MYCN silencing of 30% (range: 20–44%) and 
36% (range: 22–63%) for cationic-PEG and anionic-PEG nano-
complexes, respectively, relative to control siRNA formulations 
(p < 0.01) (Figure 7A). Therapeutic studies with RTNs were then 
conducted by six intravenous injections of siMYCN nanocom-
plexes given at 48 h intervals. Tumor retardation was observed 
for individual mice treated over time with the anionic siMYCN 
Figure 6. The Dy677-siRNA fluorescence distribution was investigated in histological sections of tumors following tail-vein injections of anionic-PEG 
A–C) targeted nanocomplexes, D–F) cationic-PEG targeted nanocomplexes, G–I) control mice, J–L) anionic-PEG non-targeting nanocomplexes, and 
M–O) cationic-PEG non-targeting nanocomplexes. The tumors were removed 24 h after the injection and the fluorescence was recorded. The cell nuclei 
were stained with DAPI (blue) and the siRNA-Dy677 in red. DAPI staining (A,D,G,J,M), siRNA-Dy677 (B,E,H,K,N), and merged images (C,F,I,L,O). Scale 
bar = 50 µm (A–I); Scale bar = 100 µm (J–O).
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formulations (Figure S4A, Supporting Information) performing 
better than their cationic counterparts (Figure S4B, Supporting 
Information), compared to control siRNA groups. This was 
confirmed by the observation that the average tumor volumes 
at day 17 post-engraftment of mice receiving siMYCN in cati-
onic complexes (when all mice were still alive) was reduced to 
≈46 mm3, whereas the average tumor volume in mice receiving 
anionic siMYCN nanocomplexes was 36 mm3 (p < 0.05), while 
the control siRNA group was ≈195 mm3 (p < 0.01), (Figure 7B). 
There was no average difference in tumor growth rates between 
cationic-PEG or anionic-PEG siMYCN nanocomplexes. The 
cationic control siRNA formulation appeared to slow tumor 
growth more than the anionic control siRNA formulations 
although this was not significant (Figure 7B) and did not lead 
to any significant effects on survival (Figure  7C). In addition, 
there was no significant adverse effect on body weight of 
mice receiving repeated doses of either the anionic or cationic 
RTNs, irrespective of whether they received therapeutic MYCN 
siRNA or control siRNA, during the whole treatment period 
(Figure S5A-F, Supporting Information).
As well as reduced tumor volumes, survival was improved 
for mice receiving siMYCN compared to those receiving con-
trol siRNA or the untreated mice (Figure  7C). By day 20, all 
untreated mice were culled due to tumor sizes exceeding 
acceptable limits. The survival time of mice that received 
anionic siMYCN formulations was 38% longer than those 
receiving anionic control siRNA nanocomplexes, whereas mice 
receiving cationic siMYCN outlived the mice receiving cationic 
controls by 50%.
Histological sections of tumors from the last surviving 
mouse from each group (control untreated mouse, cationic-PEG 
siMYCN, and anionic-PEG siMYCN) were stained with hema-
toxylin and eosin (H&E) and examined for evidence of a thera-
peutic effect on the tumor such as extent of vascularization, and 
Figure 7. In vivo silencing of MYCN and effects on tumor growth following single and multiple intravenous administrations of MYCN siRNA nanocom-
plexes. A) qRT-PCR analysis of MYCN silencing in NSG mice bearing subcutaneous Kelly tumors 48 h after intravenous administration of cationic-PEG 
and anionic-PEG nanocomplexes containing 25 μg MYCN siRNA (n = 6), control siRNA (n = 5) or untreated mice (n = 3). Silencing was normalized 
to the mean control siRNA while median values are presented by horizontal lines and asterisks indicate statistical significance (**p < 0.01). Mice were 
treated with cationic-PEG and anionic formulations containing 25 µg of MYCN or control siRNA, delivered six times intravenously, at 48 h intervals 
from day 2 to day 12 in NSG mice with Kelly cell xenografts and then B) average tumor volume was determined (n = 5 for each of the five groups; 
*p < 0.05). C) Survival of NSG mice shown in a Kaplan–Meier plot.
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necrosis (Figure S6, Supporting Information). Vascularity was 
comparable among all groups, whereas the last surviving cati-
onic-PEG mouse showed more marked tumor cell death with 
a prominent perivascular survival effect compared with the ani-
onic-PEG mouse and the control untreated mouse (Figure S6, 
Supporting Information). Histological analysis of lung, kidney, 
liver, and spleen from mice injected with cationic siRNA nano-
complexes did not reveal any observable differences from 
organs of untreated mice (Figure S7, Supporting Information).
2.6. Dose Modeling
Next, we investigated the possibility of using the experimental 
data to establish a mathematical model to describe the effects of 
siMYCN nanoparticles on neuroblastoma growth using popula-
tion K-PD modeling with a simple exponential growth model 
chosen. There was no significant improvement in fit when ani-
onic and cationic vehicles were separated. When analyzing the 
effect of the irrelevant control, fit was significantly improved 
(p  <  0.001) with the irrelevant control estimated to have 29% 
the activity of the active. Further information is provided in 
Supporting Information, with model parameter estimates 
(Table  S2, Supporting Information, and goodness-of-fit plots 
[Figure S8, Supporting Information]).
A model was successfully established using a K-PD model 
as a structural submodel, while random effects for growth rate 
constant and baseline tumor volume were also estimated, but 
no covariate was identified. The model was used to evaluate 
the K-PD properties difference between the two formulations 
of nanoparticles and no significant difference was found. Effect 
of the control irrelevant siRNA on neuroblastoma growth was 
also tested, and interestingly irrelevant siRNA appears to be 
not completely inert but exerts an inhibitory effect on neuro-
blastoma growth. SiRNAs, may display sequence dependent 
immunogenicity in mice facilitated by TLR7[30] however, in our 
control siRNA (5′-UAACGACGCGACGAACGUAATT-3′) the 
known immunostimulatory motifs, for example, 5′-UGUGU-
3′, 5′-GUCCUUCAA-3′, and 5′-UGU-3′ are missing,[30,31] which 
should reduce the risk of stimulation and so this will require 
further investigation.
3. Conclusions
The RTNs reported here showed significant MYCN silencing in 
vitro in neuroblastoma cells with little cytotoxicity. RTNs over-
come a major limitation in the development of siRNA cancer 
therapies in that they avoid significant clearance by the liver 
allowing accumulation in the tumor, probably through a leaky 
tumor/endothelial barrier, while their integrin-targeting and 
fusogenic properties enable efficient transfection of the target 
tumor cells. Anionic RTNs were as efficient and specific as 
their cationic counterparts, and, in addition, offer advantage of 
reduced systemic and cellular toxicity. In vivo, the RTNs enter 
the tumors efficiently, with little off-target biodistribution, and 
transfect tumor cells in an integrin-mediated fashion. Delivery 
of siMYCN resulted in retardation of tumor growth, improving 
survival of mice. These nanocomplexes, thus, allow for the 
specific targeted enhancement of nucleic acid delivery and 
could provide improved non-viral vectors to deliver therapeutic 
cargos in a variety of disorders.
4. Experimental Section
Materials: 1,2-di-O-octadecenyl-3-trimethylammonium propane 
(DOTMA), 1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG), 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and 1,2-dipalmitoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(DPPE-PEG2000) were purchased from Avanti Polar Lipids, Inc. (Alabaster, 
AL, USA). Integrin-targeting peptide ME27 (K16RVRRGACRGDCLG) 
and non-targeting control peptide ME72 (K16RVRRGACRGECLG) were 
synthesized by China Peptides (Shanghai, China).
siMYCNs for in vitro transfections were purchased from Eurogentec 




The in vivo siRNAs, including MYCN-3 and control siRNA 
(UGGUUUACAUGUUGUGUGA) were purchased from GE Healthcare 
(Amersham, UK) while Silencer Negative Control #1 (Irrelevant control 
siRNA 5′-UAACGACGCGACGAACGUAATT-3′) was purchased from 
Applied Biosystems (Warrington, UK). Labeled siRNAs including 
control siRNA-fluorescein (siRNA-FAM) and Dy677 control siRNA 
(siRNA-Dy677) were purchased from GE Healthcare (Amersham, UK).
Lipofectamine 2000 (L2K) was purchased from Thermo Fisher 
(Paisley, UK) and mouse serum from Sigma-Aldrich (Gillingham, UK).
Liposome Preparation and Nanocomplex Formation: The lipids, 
including cationic DOTMA, anionic DOPG, the neutral fusogenic 
lipid DOPE, and PEG-lipid DPPE-PEG2000 were dissolved in 
chloroform to a concentration of 10  mg  mL−1. Liposomes were 
prepared by preparing mixtures of lipids at the following molar ratios: 
DOTMA:DOPE (50:50), DOTMA:DOPE:DPPE-PEG2000 (49.5:49.5:1), 
and DOPG:DOPE:DPPE-PEG2000 (49.5:49.5:1). The chloroform was 
evaporated in a rotary evaporator (BÜCHI Labortechnik AG, Flawil, 
Switzerland) and the lipid film was hydrated in water followed by 
sonication at RT for 45  min to generate liposomes as described 
previously.[32]
Cationic, non-PEGylated (cationic non-PEG) nanocomplexes were 
formulated by mixing DOTMA/DOPE liposomes with peptides and 
siRNA at a weight ratio of 1:4:1, liposome:peptide:siRNA and in that 
order of mixing, with rapid mixing on addition of siRNA, followed 
by incubation for 30  min at RT to allow for complex formation. 
Cationic-PEG nanocomplexes were prepared in a similar way but with 
DOTMA/DOPE/DPPE-PEG2000 liposome instead of DOTMA/DOPE. 
The anionic-PEGylated nanocomplex formulations were prepared 
in a double-layered approach by first preparing a cationic non-PEG 
nanocomplex formulation at a weight ratio of 0.75:3:1 (DOTMA/
DOPE:liposome:peptide:siRNA), and then adding anionic-PEG 
liposomes (DOPG:DOPE:DPPE-PEG2000) at a weight ratio of 19:1 
(anionic-PEG liposome:siRNA). The mixture was incubated at RT for 
30  min then diluted for use as required. Lipofectamine 2000 (L2K) 
siRNA complexes were prepared by mixing with siRNA at a weight ratio 
of 4:1 (L2K:siRNA) followed by incubation at RT for 20 min before use.
Particle Sizing and Zeta Potential Measurement: Size and surface 
charge (ζ potential) measurements were performed with a Malvern 
Nano ZS zetasizer (Malvern, UK). Nanocomplexes were prepared 
(5 µg mL−1 with respect to siRNA) then diluted with deionized water or 
PBS to a final volume of 1  mL. Measurements were performed in the 
NanoZS at a temperature of 25 °C. DTS version 5.03 software provided 
by the manufacturer was used for data processing. Nanoparticle sizes 
and particle concentration were also determined by NTA using a 
NanoSight LM20 (NanoSight, Amesbury, UK) equipped with a sample 
chamber with a 405 nm blue laser and a Viton fluoroelastomer O-ring.[33] 
Nanocomplexes were prepared at 10 µg siRNA in 100 µL water and then 
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diluted with PBS before measurement as required. NTA measurements 
were performed at 21 °C. Each experiment was repeated at least thrice 
and the results were presented as mean hydrodynamic sizes ± S.D.[33]
Turbidity Assay: The absorbance of complexes in the absence and 
presence of mouse serum at a range of concentrations (0–50%  v/v) 
was measured at 500 nm using a FLUOstar Optima spectrophotometer 
(BMG Labtech, Aylesbury, UK) as described previously,[14e] with a 
corresponding amount of serum used as a reference.
Heparin Dissociation Assay: Briefly, 0.2  µg siRNA was mixed with 
PicoGreen reagent (1:150) (Invitrogen, Paisley, UK) at RT in 10  mm 
Tris-HCl, 1 mm EDTA, and pH 7.5 (TE) buffer, and the siRNA/PicoGreen 
mixture was then formulated into nanocomplexes as described above. 
Heparin sulfate (Sigma, Poole, UK) was added to the complexes 
formulated with PicoGreen in a range of concentrations (0.05–1 U mL−1) 
and then fluorescence (480  nm excitation peak and 520  nm emission 
peak) was measured in an OPTIMA Fluostar. In each experiment, naked 
siRNA stained with PicoGreen was used to normalize the PicoGreen 
signal detected from the complexes.
Transmission Electron Microscopy: Nanocomplexes were prepared as 
described above and were applied onto a glow-discharged 300-mesh 
copper grid coated with a Formvar/carbon support film (Agar Scientific). 
The grid was dried by blotting with filter paper then negatively stained 
with 1% w/v uranyl acetate before blotting with filter paper and air-dried. 
Imaging was performed under a Philips CM120 BioTwin TEM, operated 
at an accelerating voltage of 120 KV.
Cell Culture: Human neuroblastoma cell lines Kelly and LAN-5 were 
obtained from the American Type Culture Collection (ATCC, Teddington, 
UK) and certified as mycoplasma free. Kelly cells were cultured in 
RPMI1640+GlutaMAX (Invitrogen, Paisley, UK) supplemented with FBS 
(10%), HEPES (25 mm), and penicillin/streptomycin (100 U mL−1). LAN-5 
cells were cultured in MEM with FBS (10%), L-glutamine (2 mm),  and 
penicillin/streptomycin (100  U  mL−1). All cells were maintained in a 
humidified atmosphere of air (95%) and CO2 (5%) at 37 °C.
siRNA Transfection: Kelly or LAN-5 cells were seeded (3  ×  105 cells 
per well) in 12-well plates and then the following day when 50–60% 
confluent, nanocomplexes were prepared as above in OptiMEM (Section: 
Liposome Preparation and Nanocomplex Formation), containing 
siMYCN or control siRNA (100 nm), and transfection incubations were 
performed for 4 h. The transfection medium was replaced with complete 
media and the cells were incubated at 37  °C  for a further 48  h. Cells 
were then harvested by trypsinization and homogenized with Qiagen 
shredders (Qiagen, Crawley, UK). Total RNA was extracted from the 
homogenate using the RNeasy Kit (Qiagen, Crawley, UK) and each 
sample treated with DNase (Invitrogen, Paisley, UK) to eliminate any 
contaminating DNA. RNA samples were stored at −80 °C.
Quantitative Real-Time PCR: Total RNA (200  ng per reaction) was 
used in a one-step quantitative real-time PCR (qRT-PCR) (SensiFast 
Probe Hi-Rox One-Step Kit; Bioline, London, UK) that combines the 
reverse transcription step with the quantitative PCR (qPCR) reaction. 
Human MYCN and ACTB (encoding β-actin), were quantified by Taqman 
primers and probes (Hs00232074_m1 and Hs99999903_m1 for MYCN 
and ACTB, respectively; Thermo Fisher Scientific, Northumberland, UK). 
The qRT-PCR assays were performed in a Bio-Rad CFX96 Real-Time PCR 
Detection System with the following parameters: 45 °C for 20 min, 95 °C 
for 2  min, and then 40 cycles at 95  °C for 15  s and 60  °C for 1  min. 
Relative expression levels were calculated using the delta-delta Ct 
(2−ΔΔCt) method.[34]
Cell Viability Assay: Cell viability was assessed in 96-well plates using 
the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, 
Southampton, UK). Kelly or LAN-5 cells were transfected as above, then 
after 24 h the medium was substituted for a growth medium containing 
20 µL of CellTiter 96 Aqueous One Solution reagent, incubated for 2 h, 
then absorbance at 490 nm measured with a FLUOstar Optima (BMG 
Labtech, Aylesbury, UK). Cell viability for each complex was expressed as 
a percentage of the viability of control untreated cells. Cell proliferation 
analysis following siRNA transfections was performed 48 h later.
Propidium Iodide Staining for Sub-G1 DNA Content: Kelly cells were 
transfected with nanocomplexes then trypsinized at 24  h and fixed in 
ice-cold 70% ethanol for 30 min, rinsed twice in phosphate-citrate buffer 
(0.2 m Na2HPO4/0.1 m citric acid, pH 7.8) by centrifugation at 500 × g, 
and resuspended in propidium iodide (200 µL of 50 µg mL−1) in PBS and 
RNaseA solution (50 µL of 100 µg mL−1 in distilled water). The cells were 
analyzed with a BD LSRII flow cytometer (BD Biosciences, Wokingham, 
UK). A maximum of 10 000 events were collected per sample then data 
analyzed using Flo-jo V8 software.
Complement Activation Assays: Characterization and functional 
assessments of complement pathways were performed as described 
previously[35] by measuring increases in the serum complement-
activation products, C5a and sC5b-9, by enzyme linked immunosorbent 
assays (ELISA kits, Quidel, San Diego, USA). Complement activation 
was initiated by adding the appropriate quantities of nanocomplex 
(in 10 µL) to undiluted human serum (40 µL) in Eppendorf tubes in a 
shaking water bath at 37  °C for 30  min. Reactions were terminated by 
the addition of ice-cold sample-diluent, from the assay kit, containing 
EDTA (25  mm). Nanocomplexes were removed by centrifugation, and 
complement activation products were measured by ELISA. Control 
serum incubations contained buffers used for liposome suspension. 
Zymosan (0.2  mg  mL−1) was prepared as described before[35] and was 
used as a positive control for generating C5a and sC5b-9.
In Vivo Delivery to Xenograft Tumor Models: All animal procedures were 
approved by UCL animal care policies and were performed under Home 
Office Licenses, issued in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986 (UK). 6 to 8 weeks old, NOD-SCID 
gamma (NSG) mice of mixed gender, (Charles River, Margate, UK), were 
injected subcutaneously in the right posterior flank with 3 × 106 human 
neuroblastoma Kelly cells. After ≈2 weeks, tumors reached 8–10  mm 
in size, at which point cationic or anionic RTN complexes (100  µL in 
5% D-glucose) containing siRNA-FAM or siRNA-Dy677 (16  µg), were 
injected intravenously in the tail. The nanocomplexes were made as 
described above (Section: Liposome Preparation and Nanocomplex 
Formation) except that the final added components (siRNA for cationic 
RTNs; anionic-PEG liposome in anionic-PEG RTNs) were mixed with 
nuclease-free water to make a volume of 90  µL per sample. Following 
the final incubation, 10  µL of 50% D-glucose were added to make the 
final volume of 100 µL per injection and the RTNs were stored at 2–8 °C 
until needed. 24 or 48  h after injection, mice were either imaged live, 
or killed and tumors and organs resected and imaged using an IVIS 
Lumina Series III imaging system (Perkin Elmer, Seer Green, UK). 
Images were processed with the Living Image software (Perkin Elmer, 
Seer Green, UK).
For silencing experiments, ≈2 weeks after Kelly cells were xenografted, 
the mice were injected by tail vein with 100 µL of cationic or anionic RTN 
complexes containing 25 µg siMYCN or control siRNA in 5% D-glucose. 
48  h later the mice were culled and the tumors were collected in 
RNAlater (Invitrogen, Paisley, UK) and homogenized in lysis buffer with a 
Precellys24 tissue homogenizer (Stretton Scientific, Stretton, Derbyshire, 
UK) and then centrifuged at 14170 × g for 10 min at 4 °C. The supernatant 
was removed and centrifuged for a further 10 min at 4 °C. Total RNA was 
extracted from lysates using the RNeasy kit (Qiagen, Crawley, UK) and 
the qRT-PCR assay was performed as described above.
For tumor progression experiments, the RTN injections commenced 
when tumors were palpable. Mice received six consecutive injections 
of nanocomplexes containing 25  µg of siMYCN or control siRNA 
administered from day 2 post-engraftment (days: 2, 4, 6, 8, 10, and 
12) and tumor progression was monitored as described previously.[36] 
The tumors from the last surviving mouse of each group (cationic and 
anionic siMYCN formulations, and untreated control) were then placed 
in paraformaldehyde (PFA;4% w/v) (Sigma-Aldrich, Gillingham, UK) 
for 3 h and embedded in paraffin wax and 7 µm sections mounted on 
polylysine-coated slides. For histological analysis, sections were serially 
rehydrated and stained with H&E, followed by serial dehydration with 
ethanol and mounted with glass coverslips.
Preparation of Frozen Tissue Sections: Freshly dissected tumors from 
mice transfected with nanocomplexes containing siRNA-Dy677 were 
placed onto prelabeled tissue base molds. The tissue block was covered 
with cryo-embedding media OCT (Leica microsystems, Milton Keynes, 
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UK). Base mold containing tissue block was snap frozen in isopentane 
(VWR International, Lutterworth, UK), that had been prechilled in 
liquid nitrogen, and then transferred to a cryotome cryostat, precooled 
to −20  °C.  10  µm tissue sections were prepared using a cryotome 
and mounted on Superfrost Plus glass slides (Fisher Scientific UK, 
Loughborough, UK). The sections were dried at RT and then stored at 
−80 °C until required.
Staining of Frozen Sections: Tissue sections were rinsed in PBS 
briefly to remove any media components, then fixed in precooled 
(−20 °C) acetone for 10–15 min and rinsed with three changes of PBS, 
5  min each. Tissue sections were stained with DAPI for 15  min at RT 
in the dark, then washed with three further changes of PBS for 5 min 
each. Sections were mounted using ProLong Gold antifade mountant 
(Thermo Fisher Scientific, Hemel Hempstead, UK). Micrographs were 
taken using Leica upright fluorescence (Leica DFC310 FX) at 200× 
magnification.
Histological Analysis of Toxicity: NSG mice were injected by tail vein 
with 20  µg siRNA-Dy677 in cationic-PEG nanocomplexes and were 
sacrificed 24 h later. Untransfected mice were used as controls. Tissue 
samples from lung, liver, kidney, and spleen were fixed in 4% PFA and 
70%  ethanol. Then the organs were transferred to neutral buffered 
formalin solution (Genta Medical, York, UK) prior to 13  h of overnight 
processing on a Leica PELORIS II Tissue Processor. In brief, over 
multiple incubations, samples were dehydrated in 99% industrial 
denatured alcohol/99% industrial methylated spirit (Genta Medical, 
York, UK), cleared in xylene (Genta Medical, York, UK), and impregnated 
with CellWax Plus [S] paraffin wax (Cell Path, Newtown, Powys, UK). 
Samples were embedded using Sakura Tissue-Tek TEC 5 console 
system. Formalin-fixed-paraffin-embedded sections were generated 
at 3  µm  thickness on a Thermo Scientific Shandon Finesse ME+ 
microtome. Sections were stained on the Leica Autostainer XL ST5010, 
an automated H&E workstation, and mounted using LEICA CV5030 
automated cover slipper machine. The stained H&E sections were 
scanned on the Leica Aperio CS2 Scanner at 40× objective.
Dose Modeling: A pharmacokinetic/pharmacodynamic model was 
developed of changes in tumor volume over time with details provided 
in the Supporting Information.
Statistics: The data presented in this study were expressed as 
the mean  ±  standard deviation and were analyzed using a two-
tailed, unpaired Student’s t-test or one-way analysis of variance and 
Bonferroni’s post hoc analysis, where applicable. Non-parametric data 
were analyzed using a Mann–Whitney U test.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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